Pandion Therapeutics Presents Preclinical Data Highlighting Potential of Tissue-Tethered PD-1 Agonist to Locally Target Autoimmune Disease at the nPOD 13th Annual Scientific Meeting
22 févr. 2021 08h30 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
18 févr. 2021 08h30 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Announces Positive Top-Line Phase 1a Clinical Data Showing PT101 was Well-Tolerated and Selectively Expanded Regulatory T cells
04 janv. 2021 08h00 HE
|
Pandion Therapeutics, Inc.
-Phase 1a trial achieved primary objective of safety and tolerability-PT101 induced potent and selective expansion of regulatory T cells exceeding levels associated with clinical benefit in...
Pandion Therapeutics Appoints Katina Dorton to its Board of Directors
03 déc. 2020 08h00 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
16 nov. 2020 16h01 HE
|
Pandion Therapeutics, Inc.
- Enrollment and dosing complete in Phase 1a clinical trial of PT101; top-line results expected early 2021- PT627 systemic PD-1 agonist development candidate nominated; IND-enabling studies expected...
Pandion Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
10 nov. 2020 08h00 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020
28 oct. 2020 08h00 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit
24 sept. 2020 08h00 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Present at Morgan Stanley Global Healthcare Conference
10 sept. 2020 08h00 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update
31 août 2020 16h05 HE
|
Pandion Therapeutics, Inc.
- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024 - Expanded executive team with appointment of John S. Sundy, M.D.,...